Menu
The diagnostic test to measure proteomic biomarkers aiming to support the diagnosis of Alzheimer’s Disease.
Alzheimer’s is the most common form of dementia. The World Health Organization (WHO) considers the disease as one of the top five threats to mankind:
Toxic proteins that are responsible for the disease, begin to accumulate in the brain years before clinical symptoms occur. Today’s diagnostic procedures are highly invasive, expensive, time consuming and most importantly applied too late, when the disease has progressed too far already. Thus, an early detection is key for developing better and more effective treatments.
The current gold standard in the diagnosis of Alzheimer’s includes the examination of the key protein biomarkers that are associated with this disease: Amyloid-beta 42/40 ratio, total Tau and hyperphosphorylated Tau.
nosetestAD® measures those four gold standard proteins in nasal secretion to aiming support the diagnosis of the disease.
Amyloid-beta 40
Amyloid-beta 42
Total Tau
Hyperphosphorylated Tau
nosetestAD® is minimally invasive and therefore can be applied to patients early on.
nosetestAD® can be applied quickly and easily, which makes it broadly available and can lead to high acceptance by patients.
nosetestAD® could be applied frequently throughout the course of the patient’s journey, aiming at permitting the monitoring of disease progression and treatment response.
Want to know more about the fundamental scientific principles and how it works in detail?
